Want to see HK:1672 full AI Analyst Report?
Ascletis Pharma, Inc. (1672) Stock Statistics & Valuation Metrics
Total Valuation
Ascletis Pharma, Inc. has a market cap or net worth of HKD 5.15B. The enterprise value is HKD 8.36B.
- Market Cap
- HKD 5.15B
- Enterprise Value
- HKD 8.36B
Share Statistics
Ascletis Pharma, Inc. has 1,057,987,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,057,987,000
- Owned by Insiders
- ―
- Owned by Institutions
- 0.79%
Financial Efficiency
Ascletis Pharma, Inc.’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -24.90%.
- Return on Equity (ROE)
- -0.19
- Return on Assets (ROA)
- -0.17
- Return on Invested Capital (ROIC)
- -24.90%
- Return on Capital Employed (ROCE)
- -0.25
- Revenue Per Employee
- 9,345.622
- Profits Per Employee
- -1.66M
- Employee Count
- 217
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.80
Valuation Ratios
The current PE Ratio of Ascletis Pharma, Inc. is -7.03. Ascletis Pharma, Inc.’s PEG ratio is 0.09.
- PE Ratio
- -7.03
- PS Ratio
- 4604.57
- PB Ratio
- 1.90
- Price to FCF
- -8.69
- Price to Operating Cash Flow
- -8.63
- PEG Ratio
- 0.09
Income Statement
In the last 12 months, Ascletis Pharma, Inc. had revenue of 2.03M and earned -359.88M in profits. Earnings per share was -0.37.
- Revenue
- 2.03M
- Gross Profit
- 527.00K
- Operating Income
- -483.76M
- Pretax Income
- -359.37M
- Net Income
- -359.88M
- EBITDA
- -466.92M
- Earnings Per Share (EPS)
- -0.37
Cash Flow
In the last 12 months, operating cash flow was -500.13M and capital expenditures -1.89M, giving a free cash flow of -502.02M billion.
- Operating Cash Flow
- -500.13M
- Free Cash Flow
- -502.02M
- Free Cash Flow per Share
- -0.48
Dividends & Yields
Ascletis Pharma, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -11.51%
- Earnings Yield
- -13.72%
Stock Price Statistics
- Beta
- 1.06
- 52-Week Price Change
- -47.37%
- 50-Day Moving Average
- 8.12
- 200-Day Moving Average
- 12.24
- Relative Strength Index (RSI)
- 24.20
- Average Volume (3m)
- 2.25M
Important Dates
Ascletis Pharma, Inc. upcoming earnings date is Mar 30, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Mar 30, 2027
- Ex-Dividend Date
- ―
Financial Position
Ascletis Pharma, Inc. as a current ratio of 15.05, with Debt / Equity ratio of 0.27%
- Current Ratio
- 15.05
- Quick Ratio
- 15.04
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 3.08
- Interest Coverage Ratio
- -2949.74
Taxes
In the past 12 months, Ascletis Pharma, Inc. has paid 506.00K in taxes.
- Income Tax
- 506.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Ascletis Pharma, Inc. EV to EBITDA ratio is -5.80, with an EV/FCF ratio of -7.51.
- EV to Sales
- 3982.05
- EV to EBITDA
- -5.80
- EV to Free Cash Flow
- -7.51
- EV to Operating Cash Flow
- -7.54
Balance Sheet
Ascletis Pharma, Inc. has HKD 2.27B in cash and marketable securities with HKD 3.74M in debt, giving a net cash position of HKD 2.26B billion.
- Cash & Marketable Securities
- HKD 2.27B
- Total Debt
- HKD 3.74M
- Net Cash
- HKD 2.26B
- Net Cash Per Share
- HKD 2.14
- Tangible Book Value Per Share
- HKD 2.18
Margins
Gross margin is -863.41%, with operating margin of -70395.30%, and net profit margin of -62508.34%.
- Gross Margin
- -863.41%
- Operating Margin
- -70395.30%
- Pretax Margin
- -62444.55%
- Net Profit Margin
- -62508.34%
- EBITDA Margin
- -68667.15%
- EBIT Margin
- -70438.28%
Analyst Forecast
The average price target for Ascletis Pharma, Inc. is HKD 14.20, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- HKD 14.20
- Price Target Upside
- 189.69% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 2
- Revenue Growth Forecast
- -59.39%
- EPS Growth Forecast
- -130.04%
Scores
- Smart Score
- 2
- AI Score
- 44
